1. Home
  2. ADAG

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Founded: 2011 Country:
China
China
Employees: N/A City: N/A
Market Cap: 98.5M IPO Year: 2021
Target Price: $5.00 AVG Volume (30 days): 33.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.44 EPS Growth: N/A
52 Week Low/High: $1.10 - $4.38 Next Earning Date: 05-28-2024
Revenue: $18,111,491 Revenue Growth: 78.00%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: